Swathi Pathadka1, Vincent K C Yan1, Xue Li1,2,3, Gary Tse4, Eric Y F Wan1,5, Hayden Lau1,6, Wallis C Y Lau1,7, David C W Siu8, Esther W Chan1, Ian C K Wong1,7. 1. Department of Pharmacology and Pharmacy, Li Ka Shing Faculty of Medicine, Centre for Safe Medication Practice and Research, University of Hong Kong, Hong Kong, China. 2. Department of Paediatrics and Adolescent Medicine, Li Ka Shing Faculty of Medicine, University of Hong Kong, Hong Kong, China. 3. Department of Social Work and Social Administration, Faculty of Social Science, University of Hong Kong, Hong Kong, China. 4. Xiamen Cardiovascular Hospital, Xiamen University, Xiamen, China. 5. Department of Family Medicine and Primary Care, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China. 6. Department of Accident & Emergency, Li Ka Shing Faculty of Medicine, Queen Mary Hospital, University of Hong Kong, Hong Kong, China. 7. Research Department of Practice and Policy, University College of London School of Pharmacy, London, United Kingdom. 8. Department of Medicine, Li Ka Shing Faculty of Medicine, The University of Hong Kong, Hong Kong, China.
Abstract
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45-0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45-0.77), all-cause mortality (HR 0.51; 95% CI, 0.36-0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70-1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39-1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population.
Background: The effect of sacubitril/valsartan on survival and hospitalization risk in older patients with heart failure has not been explored. We aimed to investigate the risk of hospitalization and mortality with the use of sacubitril/valsartan vs. enalapril in patients with heart failure. Methods: This was a population-based cohort study using the Hong Kong-wide electronic healthcare database. Patients diagnosed with heart failure and newly prescribed sacubitril/valsartan or enalapril between July 2016 and June 2019 were included. The risk of primary composite outcome of cardiovascular mortality or heart failure-related hospitalization, all-cause hospitalization, heart failure-related hospitalization, cardiovascular mortality and all-cause mortality were compared using Cox regression with inverse probability treatment weighting. Additional analysis was conducted by age stratification. Results: Of the 44,503 patients who received sacubitril/valsartan or enalapril, 3,237 new users (sacubitril/valsartan, n = 1,056; enalapril, n = 2,181) with a diagnosis of heart failure were identified. Compared with enalapril, sacubitril/valsartan users were associated with a lower risk of primary composite outcome [hazard ratio (HR) 0.58; 95% confidence interval (CI), 0.45-0.75], heart failure-related hospitalization (HR 0.59; 95% CI, 0.45-0.77), all-cause mortality (HR 0.51; 95% CI, 0.36-0.74) and borderline non-significant reductions in all-cause hospitalization (HR 0.85; 95% CI, 0.70-1.04) and cardiovascular mortality (HR 0.63; 95% CI, 0.39-1.02). The treatment effect of sacubitril/valsartan remains unaltered in the patient subgroup age ≥ 65 years (73%). Conclusions: In real-world settings, sacubitril/valsartan was associated with improved survival and reduced heart failure-related hospitalization compared to enalapril in Asian patients with heart failure. The effectiveness remains consistent in the older population.
Authors: Esther W Chan; Wallis C Y Lau; Wai K Leung; Michael T C Mok; Ying He; Teresa S M Tong; Ian C K Wong Journal: Gastroenterology Date: 2015-05-08 Impact factor: 22.682
Authors: Dana Drzayich Antol; Adrianne Waldman Casebeer; Richard W DeClue; Stephen Stemkowski; Patricia A Russo Journal: Adv Ther Date: 2018-05-17 Impact factor: 3.845
Authors: Nicholas Y Tan; Lindsey R Sangaralingham; S Jeson Sangaralingham; Xiaoxi Yao; Nilay D Shah; Shannon M Dunlay Journal: JACC Heart Fail Date: 2019-12-11 Impact factor: 12.035
Authors: Piotr Ponikowski; Adriaan A Voors; Stefan D Anker; Héctor Bueno; John G F Cleland; Andrew J S Coats; Volkmar Falk; José Ramón González-Juanatey; Veli-Pekka Harjola; Ewa A Jankowska; Mariell Jessup; Cecilia Linde; Petros Nihoyannopoulos; John T Parissis; Burkert Pieske; Jillian P Riley; Giuseppe M C Rosano; Luis M Ruilope; Frank Ruschitzka; Frans H Rutten; Peter van der Meer Journal: Eur Heart J Date: 2016-05-20 Impact factor: 29.983
Authors: Angel Y S Wong; Adrian Root; Ian J Douglas; Celine S L Chui; Esther W Chan; Yonas Ghebremichael-Weldeselassie; Chung-Wah Siu; Liam Smeeth; Ian C K Wong Journal: BMJ Date: 2016-01-14
Authors: Alexander T Sandhu; Daniel A Ollendorf; Richard H Chapman; Steven D Pearson; Paul A Heidenreich Journal: Ann Intern Med Date: 2016-08-30 Impact factor: 25.391
Authors: Chengsheng Ju; Jiandong Zhou; Sharen Lee; Martin Sebastian Tan; Tong Liu; George Bazoukis; Kamalan Jeevaratnam; Esther W Y Chan; Ian Chi Kei Wong; Li Wei; Qingpeng Zhang; Gary Tse Journal: ESC Heart Fail Date: 2021-06-03